亚辉龙公告称，预计2025年度归属于母公司所有者的净利润为2000万元至3000万元，同比减少90.05% 至93.37%；扣非净利润6500万元至8500万元，同比减少70.42%至77.38%。业绩下降主因行业政策致国 内市场需求减少、营收和毛利率下降，交易性金融资产亏损及计提资产减值准备。不过，海外业务稳定 增长，术前八项全系列试剂IVDR CE认证全覆盖。产品研发成果丰硕，国内化学发光产品菜单扩至180 项，多项产品获认证或授权。 ...

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a decrease of 88.70% to 92.47% compared to the previous year, with net profit attributed to shareholders estimated between 4 million to 6 million yuan [1] Group 1: Financial Performance - The projected net profit for 2025 is between 4 million to 6 million yuan, indicating a substantial year-on-year decrease [1] - The net profit excluding non-recurring losses is expected to be between -12 million to -7 million yuan [1] Group 2: Factors Affecting Performance - The decline in performance is primarily due to the impact of the U.S. FDA import warnings and increased tariffs, which have altered the company's product sales structure and reduced overall gross profit margins [1] - The company is accelerating the construction and production of its facility in Cambodia to adapt to external environmental changes, which has led to increased fixed costs and initial production inefficiencies [1] - Additional costs have been incurred for the registration and certification of new products as part of the company's business layout strategy [1] - The company has recognized impairment losses on certain assets based on prudence principles in accordance with accounting standards [1]

每经AI快讯，天臣医疗1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 与上年同期相比，将增加3100万元~3700万元，同比增加59.74%~71.3%。业绩变动主要原因是，报告期 内，公司坚持创新驱动战略，强化国内、外双轮驱动，持续为国内外客户提供丰富的产品矩阵，报告期 内腔镜吻合器类产品销售收入持续稳定增长。报告期内，由于汇率波动，导致公司持有外币货币性项目 产生的汇兑收益同比增加。 （记者 王晓波） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

格隆汇1月30日｜有投资者在互动平台向祥生医疗提问：贵公司在超声医学影像和人工智能领域深耕多 年，请问公司在超声波脑机接口方向是否有技术布局或先发优势？ 祥生医疗回复称，公司已布局超声 人工智能技术多年，推出的SonoAI软件在多个病种或临床领域，如乳腺、肝脏、心血管、颈动脉、甲 状腺、小器官和妇产科等方面均取得了实质性的进展，核心技术已经广泛搭载于高端推车彩超和便携新 产品线。目前，公司暂不涉及脑机接口相关技术研究。 ...

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 4 million to 6 million yuan, which represents a year-on-year decrease of 88.70% to 92.47% [1] Group 1 - The decline in net profit is attributed to ongoing impacts from the U.S. Food and Drug Administration (FDA) import warnings and increased tariffs imposed by the U.S. [1] - Changes in the company's product sales structure have occurred as a result of these external factors, leading to a decrease in the overall gross profit margin of the products [1]

天臣医疗公告，预计2025年年度实现归属于母公司所有者的净利润与上年同期相比，将增加3100万元到 3700万元，同比增加59.74%到71.30%。预计2025年年度实现归属于母公司所有者的扣除非经常性损益 的净利润与上年同期相比，将增加2700万元到3100万元，同比增加57.77%到66.32%。报告期内，公司 坚持创新驱动战略，强化国内、外双轮驱动，持续为国内外客户提供丰富的产品矩阵，报告期内腔镜吻 合器类产品销售收入持续稳定增长。报告期内，由于汇率波动，导致公司持有外币货币性项目产生的汇 兑收益同比增加。 ...

格隆汇1月30日丨赛诺医疗(688108.SH)公布2025年度业绩预增公告，报告期内，预计实现归属于上市公 司股东的净利润与上年同期相比将大幅增长：预计实现归属于上市公司股东的净利润为4,300万元至 5,000万元，较上年同期增加4,150万元至4,850万元，同比增长2,767%至3,233%。报告期内，预计实现归 属于上市公司股东的扣除非经常性损益后的净利润实现扭亏为盈：预计实现归属于上市公司股东的扣除 非经常性损益后的净利润为3,000万元至3,580万元，较上年同期增加4,752万元至5,332万元，同比增长 271%至304%。 报告期内，公司球囊和支架产品的销量同比大幅增长，产品的规模效应进一步显现，从而带动单位产品 成本同比大幅下降；然而单位成本下降对营业成本的节约效应略小于销量增长带来的成本增加影响，因 此预计营业成本同比小幅增长。 ...

天臣医疗公告称，预计2025年年度归属于母公司所有者的净利润增加3100.00万元到3700.00万元，同比 增加59.74%到71.30%；扣非净利润增加2700.00万元到3100.00万元，同比增加57.77%到66.32%。上年同 期净利润为5189.48万元，扣非净利润为4674.08万元。业绩增长主要因报告期内腔镜吻合器类产品销售 收入稳定增长，以及汇率波动使汇兑收益同比增加。预告未经审计，具体数据以年报为准。 ...

华兰股份公告，控股股东江阴华兰机电科技有限公司于2026.01.29质押170万股，占其持股4.62%、占公 司总股本1.04%，质权人为中国农业银行股份有限公司江阴分行，质押用途为二级市场证券投资(增持公 司股份)。本次后控股股东及一致行动人累计质押股份170万股，占所持股份3.43%、占公司总股本 1.04%。 ...

Core Viewpoint - Kangtai Medical (300869.SZ) has recently obtained a medical device registration certificate for a non-invasive ventilator, model R100ST, from the Hebei Provincial Drug Administration, which is intended for patients with mild to moderate respiratory failure or obstructive sleep apnea (OSA) [1] Group 1 - The acquisition of the registration certificate enhances the company's product line and improves its core competitiveness [1] - The actual sales performance of the product will depend on market promotion effectiveness and demand [1] - The company is currently unable to accurately predict the impact on future operating income [1]